Recida Therapeutics, a Menlo Park, CA-based developer of novel therapeutics for serious antibiotic-resistant infections, raised $8.5M in Series A financing.
The round was led by Frazier Healthcare Partners.
Co-founded by Chief Executive Officer James Ge, MD, PhD, Vernon Jiang, PhD, George H. Talbot, MD, and Paul Eckburg, MD, Recida Therapeutics is a biopharmaceutical company focused on the development of novel therapeutics for serious antibiotic-resistant infections. Its lead program, RC-01, is a novel, IND-stage LpxC inhibitor for the treatment of multidrug-resistant gram-negative infections.
Recida has licensed development and commercialization rights to RC-01 from FUJIFILM Toyama Chemical Co. Ltd. for all territories outside Japan.
The company intends to a submit an Investigational New Drug application (IND) for RC-01 to the U.S. Food and Drug Administration (FDA) in the first quarter of 2019.
In addition, Recida received an up to $4.4M award from CARB-X to fund the preparation of the IND application, a Phase 1 trial to be completed in 2019 and drug product manufacturing to support subsequent Phase 2 studies. CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, https://carb-x.org/) is a Boston University global partnership funded by the U.S. Biomedical Advanced Research and Development Authority (BARDA), the Wellcome Trust, the U.K. Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund, and the Bill & Melinda Gates Foundation, with in-kind support from National Institute of Allergy and Infectious Diseases (NIAID), a part of the U.S. National Institutes of Health (NIH).
The company also entered into a partnership with MicuRx Pharmaceuticals, Inc. for development and commercialization of RC-01 in the greater China region.
FinSMEs
09/02/2019